RNA

Atrium Therapeutics, Inc. launched as a newly independent, publicly traded company on February 27, 2026, following its spin-off from Avidity Biosciences, Inc. after Novartis AG's acquisition of Avidity. Key stock events in the past six months include reporting first-quarter 2026 financial results and earning a $15 million milestone payment from Bristol Myers Squibb on May 14, 2026. The company reported its second-quarter 2026 financial results on August 13, 2026. Inducement grants under Nasdaq Listing Rule 5635(c)(4) were announced on August 20, 2026, and September 21, 2026. Atrium Therapeutics announced its participation in upcoming investor conferences on September 2, 2026. On October 8, 2026, the company announced a $50 million private placement financing, expected to fund operations through 2028 and support its lead product candidates. The stock has experienced a significant decline over the past year, dropping from $42.63 to $8.29, and further to $7.84, losing approximately 40% since June 30, 2026, primarily due to deepening financial losses, increased operating expenses, and funding challenges related to its precision cardiology SpinCo.